Jorge Rodriguez-Roda

Jorge Rodriguez-Roda

Auto-generated profile, based on publicly available information

Jorge Rodriguez-Roda

Department of Cardiac Surgery, Ramon y Cajal University Hospital, Madrid, Spain

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2021 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
FBFabio Barili
Fabio Barili
NFNicholas Freemantle
Nicholas Freemantle
FMFrancesco Musumeci
Francesco Musumeci
BMBarbara Martin
Barbara Martin
AAAmedeo Anselmi
Amedeo Anselmi
APAlessandro Parolari
Alessandro Parolari
OBJECTIVES: The incidence of outcomes in trials comparing transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR) is expected to be different in the short and long term. We planned a meta-analysis of reconstructed time-to-event data from trials comparing TAVI and SAVR to evaluate their time-varying effects on outcomes. METHODS: We performed a systematic review of the literature from January 2007 through September 2021 on Medline, Embase, the Cochrane Central Register of Controlled Trials and specialistic websites, including randomized trials with allocation to TAVI or SAVR that reported at least 1-year follow-up and that graphed Kaplan–Meier curves of end points. The comparisons were done with grouped frailty Cox models in a landmark framework and fully parametric models. RESULTS: Seven trials were included (7770 participants). TAVI showed a lower incidence of the composite of death or stroke in the first 6 months [risk-stratified hazard ratio (HR) 0.66, 95% confidence interval (CI) 0.56–0.77, P-value <0.001], with an HR reversal after 24 months favouring SAVR (risk-stratified HR 1.25; 95% CI 1.08–1.46; P-value 0.003). These outcomes were confirmed for all-cause death (risk-stratified HR after 24 months 1.18; 95% CI 1.03–1.35; P-value 0.01). TAVI was also associated with an increased incidence of rehospitalization after 6 months (risk-stratified HR 1.42; 95% CI 1.06–1.91; P-value 0.018) that got worse after 24 months (risk-stratified HR 1.67; 95% CI 1.24–2.24; P-value <0.001). CONCLUSIONS: Although it could appear that there is no difference between TAVI and SAVR in the 5-year cumulative results, TAVI shows a strong protective effect in the short term that runs out after 1 year. TAVI becomes a risk factor for all-cause mortality and the composite end point after 24 months and for rehospitalization after 6 months.

30 November 2021 in Metro Ciencia
Verified
Journal Article
Open access
EFEdmundo Fajardo-Rodriguez
Edmundo Fajardo-Rodriguez
JMJavier Miguelena-Hycka
Javier Miguelena-Hycka
JLJose Lopez-Menendez
Jose Lopez-Menendez
MPMercedes Liliana Castro Pinto
Mercedes Liliana Castro Pinto
RPRafael Muñoz Pérez
Rafael Muñoz Pérez
JRJorge Rodriguez-Roda
Jorge Rodriguez-Roda
La perforación tardía de miocardio (PTMI) secundaria a un dispositivo electrónico intracardiaco (DEI), es una complicación poco frecuente pero que puede ser mortal.

30 November 2021 in Metro Ciencia
Verified
Journal Article
Open access
PDF file
EFEdmundo Fajardo-Rodriguez
Edmundo Fajardo-Rodriguez
JLJose Lopez-Menendez
Jose Lopez-Menendez
MPMercedes Liliana Castro Pinto
Mercedes Liliana Castro Pinto
MGMiren Martín García
Miren Martín García
RPRafael Muñoz Pérez
Rafael Muñoz Pérez
JRJorge Rodriguez-Roda
Jorge Rodriguez-Roda
La cirugía de revascularización coronaria (CABG) es el tratamiento más efectivo en la cardiopatía isquémica, siendo la vena safena mayor el injerto más utilizado a nivel mundial. Objetivo. El objetivo principal de este trabajo fue evaluar en los grupos de Duragraft y solución salina heparinizada las incidencias de eventos cardiovasculares mayores (MACES) en una variable compuesta por (Muerte, infarto de miocardio (IM) y nueva revascularización) en un periodo de 12 meses posterior a la cirugía.